Gastric mucous secretion

Gastric mucous secretion is not a molecule or receptor but instead a physiological process carried out mainly by mucous (mucoid) cells and specialized epithelial cells in the stomach. The gastric mucosa secretes a gel-like mucus that forms a critical barrier on the stomach lining, protecting the underlying tissue from autodigestion by gastric acid and digestive enzymes[8][9][2]. The main molecular components of this barrier are mucins (notably MUC5AC and MUC6 in the stomach) produced and secreted by goblet cells, surface epithelial cells, and mucous neck cells[2][8]. This secretion is tightly regulated by neural (vagus nerve), endocrine (gastrin, prostaglandins), and paracrine factors. Prostaglandins, cholinergic nerve stimulation, neuropeptides, and direct mechanical or chemical stimulation can acutely increase mucous secretion, enhancing mucosal protection[7][8]. Several drugs, such as prostaglandin analogs (misoprostol), act by increasing mucous and bicarbonate secretion, thereby protecting the mucosa from acid-induced injury[8]. Disruption or deficiency in this mucous layer is implicated in diseases like peptic ulcer and gastritis. Because gastric mucous secretion is a process rather than a discrete molecular target (like a receptor, enzyme, channel, or transporter), it does not have a canonical abbreviation, does not constitute a direct drug target, and does not fit into conventional molecular classifications. Targeting mucous secretion pharmacologically aims to modulate the protective barrier rather than interact directly with a molecular "target"[8][7][2]. In conclusion, "gastric mucous secretion" describes a property of the gastric epithelium, not a molecular entity, and is not, in itself, a therapeutic target. The correct entries for canonical name and related fields should be the specific mucins (e.g., "Mucin 5AC") or the mucus-secreting cells themselves.

Stimulation of mucous secretion and epithelial cytoprotection